Non-Hodgkin Lymphoma - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 1065 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Non-Hodgkin Lymphoma - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Non-Hodgkin Lymphoma - Pipeline Review, H1 2016', provides an overview of the Non-Hodgkin Lymphoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma
- The report reviews pipeline therapeutics for Non-Hodgkin Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Non-Hodgkin Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Non-Hodgkin Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Non-Hodgkin Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
Introduction 8
Non-Hodgkin Lymphoma Overview 9
Therapeutics Development 10
Non-Hodgkin Lymphoma - Therapeutics under Development by Companies 12
Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes 22
Non-Hodgkin Lymphoma - Pipeline Products Glance 24
Non-Hodgkin Lymphoma - Products under Development by Companies 28
Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes 46
Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development 48
Non-Hodgkin Lymphoma - Therapeutics Assessment 172
Drug Profiles 198
Non-Hodgkin Lymphoma - Recent Pipeline Updates 644
Non-Hodgkin Lymphoma - Dormant Projects 1009
Non-Hodgkin Lymphoma - Discontinued Products 1026
Non-Hodgkin Lymphoma - Product Development Milestones 1031
Appendix 1039

List of Tables

Number of Products under Development for Non-Hodgkin Lymphoma, H1 2016 35
Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H1 2016 36
Number of Products under Development by Companies, H1 2016 37
Number of Products under Development by Companies, H1 2016 (Contd..1) 38
Number of Products under Development by Companies, H1 2016 (Contd..2) 39
Number of Products under Development by Companies, H1 2016 (Contd..3) 40
Number of Products under Development by Companies, H1 2016 (Contd..4) 41
Number of Products under Development by Companies, H1 2016 (Contd..5) 42
Number of Products under Development by Companies, H1 2016 (Contd..6) 43
Number of Products under Development by Companies, H1 2016 (Contd..7) 44
Number of Products under Development by Companies, H1 2016 (Contd..8) 45
Number of Products under Development by Companies, H1 2016 (Contd..9) 46
Number of Products under Investigation by Universities/Institutes, H1 2016 48
Comparative Analysis by Late Stage Development, H1 2016 49
Comparative Analysis by Clinical Stage Development, H1 2016 50
Comparative Analysis by Early Stage Development, H1 2016 51
Comparative Analysis by Unknown Stage Development, H1 2016 52
Products under Development by Companies, H1 2016 53
Products under Development by Companies, H1 2016 (Contd..1) 54
Products under Development by Companies, H1 2016 (Contd..2) 55
Products under Development by Companies, H1 2016 (Contd..3) 56
Products under Development by Companies, H1 2016 (Contd..4) 57
Products under Development by Companies, H1 2016 (Contd..5) 58
Products under Development by Companies, H1 2016 (Contd..6) 59
Products under Development by Companies, H1 2016 (Contd..7) 60
Products under Development by Companies, H1 2016 (Contd..8) 61
Products under Development by Companies, H1 2016 (Contd..9) 62
Products under Development by Companies, H1 2016 (Contd..10) 63
Products under Development by Companies, H1 2016 (Contd..11) 64
Products under Development by Companies, H1 2016 (Contd..12) 65
Products under Development by Companies, H1 2016 (Contd..13) 66
Products under Development by Companies, H1 2016 (Contd..14) 67
Products under Development by Companies, H1 2016 (Contd..15) 68
Products under Development by Companies, H1 2016 (Contd..16) 69
Products under Development by Companies, H1 2016 (Contd..17) 70
Products under Investigation by Universities/Institutes, H1 2016 71
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 72
Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2016 73
Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H1 2016 74
Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc., H1 2016 75
Non-Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 76
Non-Hodgkin Lymphoma - Pipeline by Actelion Ltd, H1 2016 77
Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016 78
Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H1 2016 79
Non-Hodgkin Lymphoma - Pipeline by Affimed GmbH , H1 2016 80
Non-Hodgkin Lymphoma - Pipeline by Allinky Biopharma, H1 2016 81
Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corporation, H1 2016 82
Non-Hodgkin Lymphoma - Pipeline by Amgen Inc., H1 2016 83
Non-Hodgkin Lymphoma - Pipeline by Angimmune LLC, H1 2016 84
Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H1 2016 85
Non-Hodgkin Lymphoma - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016 86
Non-Hodgkin Lymphoma - Pipeline by Arno Therapeutics, Inc., H1 2016 87
Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc., H1 2016 88
Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H1 2016 89
Non-Hodgkin Lymphoma - Pipeline by Atara Biotherapeutics, Inc., H1 2016 90
Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H1 2016 91
Non-Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 92
Non-Hodgkin Lymphoma - Pipeline by BioAtla, LLC, H1 2016 93
Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H1 2016 94
Non-Hodgkin Lymphoma - Pipeline by BioLineRx, Ltd., H1 2016 95
Non-Hodgkin Lymphoma - Pipeline by Bionovis SA, H1 2016 96
Non-Hodgkin Lymphoma - Pipeline by BioSight Ltd., H1 2016 97
Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 98
Non-Hodgkin Lymphoma - Pipeline by Boston Biomedical, Inc., H1 2016 99
Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016 100
Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences, Inc., H1 2016 101
Non-Hodgkin Lymphoma - Pipeline by Celgene Corporation, H1 2016 102
Non-Hodgkin Lymphoma - Pipeline by Cell Medica Limited, H1 2016 103
Non-Hodgkin Lymphoma - Pipeline by Celldex Therapeutics, Inc., H1 2016 104
Non-Hodgkin Lymphoma - Pipeline by Cellectis S.A., H1 2016 105
Non-Hodgkin Lymphoma - Pipeline by Celltrion, Inc., H1 2016 106
Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 107
Non-Hodgkin Lymphoma - Pipeline by Celon Pharma Sp. z o.o., H1 2016 108
Non-Hodgkin Lymphoma - Pipeline by CerRx, Inc., H1 2016 109
Non-Hodgkin Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H1 2016 110
Non-Hodgkin Lymphoma - Pipeline by Clonz Biotech Private Limited, H1 2016 111
Non-Hodgkin Lymphoma - Pipeline by Coherus BioSciences, Inc., H1 2016 112
Non-Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016 113
Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016 114
Non-Hodgkin Lymphoma - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 115
Non-Hodgkin Lymphoma - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016 116
Non-Hodgkin Lymphoma - Pipeline by Eisai Co., Ltd., H1 2016 117
Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H1 2016 118
Non-Hodgkin Lymphoma - Pipeline by EpiZyme, Inc., H1 2016 119
Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 120
Non-Hodgkin Lymphoma - Pipeline by Formula Pharmaceuticals, Inc., H1 2016 121
Non-Hodgkin Lymphoma - Pipeline by Galderma S.A., H1 2016 122
Non-Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H1 2016 123
Non-Hodgkin Lymphoma - Pipeline by Genosco, H1 2016 124
Non-Hodgkin Lymphoma - Pipeline by Genzyme Corporation, H1 2016 125
Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016 126
Non-Hodgkin Lymphoma - Pipeline by Grupo Ferrer Internacional, S.A., H1 2016 127
Non-Hodgkin Lymphoma - Pipeline by iDD biotech SAS, H1 2016 128
Non-Hodgkin Lymphoma - Pipeline by IGF Oncology, LLC., H1 2016 129
Non-Hodgkin Lymphoma - Pipeline by Immune Design Corp., H1 2016 130
Non-Hodgkin Lymphoma - Pipeline by ImmunoGen, Inc., H1 2016 131
Non-Hodgkin Lymphoma - Pipeline by Immunomedics, Inc., H1 2016 132
Non-Hodgkin Lymphoma - Pipeline by Incyte Corporation, H1 2016 133
Non-Hodgkin Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016 134
Non-Hodgkin Lymphoma - Pipeline by Innate Pharma S.A., H1 2016 135
Non-Hodgkin Lymphoma - Pipeline by Innovent Biologics, Inc., H1 2016 136
Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H1 2016 137
Non-Hodgkin Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2016 138
Non-Hodgkin Lymphoma - Pipeline by Kainos Medicine, Inc., H1 2016 139
Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 140
Non-Hodgkin Lymphoma - Pipeline by Komipharm International Co., Ltd., H1 2016 141
Non-Hodgkin Lymphoma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 142
Non-Hodgkin Lymphoma - Pipeline by MedImmune, LLC, H1 2016 143
Non-Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H1 2016 144
Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H1 2016 145
Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 146
Non-Hodgkin Lymphoma - Pipeline by miRagen Therapeutics, Inc., H1 2016 147
Non-Hodgkin Lymphoma - Pipeline by Mirna Therapeutics, Inc., H1 2016 148
Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H1 2016 149
Non-Hodgkin Lymphoma - Pipeline by Mundipharma International Ltd, H1 2016 150
Non-Hodgkin Lymphoma - Pipeline by NantKwest, Inc., H1 2016 151
Non-Hodgkin Lymphoma - Pipeline by Neumedicines Inc., H1 2016 152
Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2016 153
Non-Hodgkin Lymphoma - Pipeline by NovaLead Pharma Pvt. Ltd., H1 2016 154
Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2016 155
Non-Hodgkin Lymphoma - Pipeline by OncoSec Medical Incorporated, H1 2016 156
Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 157
Non-Hodgkin Lymphoma - Pipeline by Onxeo SA, H1 2016 158
Non-Hodgkin Lymphoma - Pipeline by Oxford BioTherapeutics Ltd, H1 2016 159
Non-Hodgkin Lymphoma - Pipeline by Panacea Biotec Limited, H1 2016 160
Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc., H1 2016 161
Non-Hodgkin Lymphoma - Pipeline by Pharma Mar, S.A., H1 2016 162
Non-Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2016 163
Non-Hodgkin Lymphoma - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016 164
Non-Hodgkin Lymphoma - Pipeline by Polyphor Ltd., H1 2016 165
Non-Hodgkin Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2016 166
Non-Hodgkin Lymphoma - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 167
Non-Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016 168
Non-Hodgkin Lymphoma - Pipeline by Richter Gedeon Nyrt., H1 2016 169
Non-Hodgkin Lymphoma - Pipeline by Sanofi, H1 2016 170
Non-Hodgkin Lymphoma - Pipeline by Sareum Holdings Plc, H1 2016 171
Non-Hodgkin Lymphoma - Pipeline by SciTech Development, LLC , H1 2016 172
Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016 173
Non-Hodgkin Lymphoma - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2016 174
Non-Hodgkin Lymphoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016 175
Non-Hodgkin Lymphoma - Pipeline by Shanghai Pharmaceutical Co., Ltd., H1 2016 176
Non-Hodgkin Lymphoma - Pipeline by SialoTec GmbH , H1 2016 177
Non-Hodgkin Lymphoma - Pipeline by Sigma-Tau S.p.A., H1 2016 178
Non-Hodgkin Lymphoma - Pipeline by Solasia Pharma K.K., H1 2016 179
Non-Hodgkin Lymphoma - Pipeline by Soligenix, Inc., H1 2016 180
Non-Hodgkin Lymphoma - Pipeline by Sorrento Therapeutics, Inc., H1 2016 181
Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 182
Non-Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H1 2016 183
Non-Hodgkin Lymphoma - Pipeline by Supratek Pharma Inc., H1 2016 184
Non-Hodgkin Lymphoma - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 185
Non-Hodgkin Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 186
Non-Hodgkin Lymphoma - Pipeline by Targazyme, Inc., H1 2016 187
Non-Hodgkin Lymphoma - Pipeline by TetraLogic Pharmaceuticals, H1 2016 188
Non-Hodgkin Lymphoma - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 189
Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2016 190
Non-Hodgkin Lymphoma - Pipeline by Theravectys SA, H1 2016 191
Non-Hodgkin Lymphoma - Pipeline by Transgene Biotek Limited, H1 2016 192
Non-Hodgkin Lymphoma - Pipeline by Trillium Therapeutics Inc., H1 2016 193
Non-Hodgkin Lymphoma - Pipeline by Unum Therapeutics, Inc., H1 2016 194
Non-Hodgkin Lymphoma - Pipeline by Xenetic Biosciences (UK) Limited, H1 2016 195
Non-Hodgkin Lymphoma - Pipeline by Zymeworks Inc., H1 2016 196
Assessment by Monotherapy Products, H1 2016 197
Assessment by Combination Products, H1 2016 198
Number of Products by Stage and Target, H1 2016 200
Number of Products by Stage and Mechanism of Action, H1 2016 211
Number of Products by Stage and Route of Administration, H1 2016 220
Number of Products by Stage and Molecule Type, H1 2016 222
Non-Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016 669
Non-Hodgkin Lymphoma - Dormant Projects, H1 2016 1034
Non-Hodgkin Lymphoma - Dormant Projects (Contd..1), H1 2016 1035
Non-Hodgkin Lymphoma - Dormant Projects (Contd..2), H1 2016 1036
Non-Hodgkin Lymphoma - Dormant Projects (Contd..3), H1 2016 1037
Non-Hodgkin Lymphoma - Dormant Projects (Contd..4), H1 2016 1038
Non-Hodgkin Lymphoma - Dormant Projects (Contd..5), H1 2016 1039
Non-Hodgkin Lymphoma - Dormant Projects (Contd..6), H1 2016 1040
Non-Hodgkin Lymphoma - Dormant Projects (Contd..7), H1 2016 1041
Non-Hodgkin Lymphoma - Dormant Projects (Contd..8), H1 2016 1042
Non-Hodgkin Lymphoma - Dormant Projects (Contd..9), H1 2016 1043
Non-Hodgkin Lymphoma - Dormant Projects (Contd..10), H1 2016 1044
Non-Hodgkin Lymphoma - Dormant Projects (Contd..11), H1 2016 1045
Non-Hodgkin Lymphoma - Dormant Projects (Contd..12), H1 2016 1046
Non-Hodgkin Lymphoma - Dormant Projects (Contd..13), H1 2016 1047
Non-Hodgkin Lymphoma - Dormant Projects (Contd..14), H1 2016 1048
Non-Hodgkin Lymphoma - Dormant Projects (Contd..15), H1 2016 1049
Non-Hodgkin Lymphoma - Dormant Projects (Contd..16), H1 2016 1050
Non-Hodgkin Lymphoma - Discontinued Products, H1 2016 1051
Non-Hodgkin Lymphoma - Discontinued Products (Contd..1), H1 2016 1052
Non-Hodgkin Lymphoma - Discontinued Products (Contd..2), H1 2016 1053
Non-Hodgkin Lymphoma - Discontinued Products (Contd..3), H1 2016 1054
Non-Hodgkin Lymphoma - Discontinued Products (Contd..4), H1 2016 1055